We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Vaccine Design and Testing – News and Features

Photograph of a vaccine vial with a needle drawing liquid

HIV Vaccine Candidate Induces Broadly Neutralizing Antibodies in Humans

A trial HIV vaccine has triggered low levels of HIV bnAbs in humans. The findings provide proof that a vaccine can elicit bnAbs to fight diverse strains of HIV and that it can initiate the process within weeks after just two immunizations.
A healthcare worker wearing a visor and mask prepares a vaccine.

COVID-19 Re-Vaccinations Elicit Neutralizing Antibodies Against Future Variants

Re-vaccination against SARS-CoV-2 promotes the development of broadly inhibitory antibodies against a wide range of variants, which supports the use of yearly booster vaccines.
Cancer cells.

Vaccine Adjuvant Promotes Strong Anti-Tumor Immunity in Animal Models

They have discovered that a vaccine adjuvant – or “booster” – called C100 promotes potent anti-tumour immunity when it is injected directly into tumours in an animal model.
A clinician holds the results of a brain scan.

Developing a Personalized Vaccine Against Cancerous Brain Tumors

Pairing a personalized dendritic cell vaccine with an immune-boosting compound improves the immune response to malignant gliomas.
Synthetic biologists inserted genes from the soap bark tree and other organisms into yeast to create a biosynthetic pathway for building a complex molecule called QS-21, a powerful adjuvant used in vaccines. The chemical structure of QS-21 is in the background.

Vaccine Adjuvant Made in Yeast Could Lower Costs and Boost Availability

Many vaccines, including the Novavax COVID-19 vaccine, contain adjuvants that stimulate the immune system to mount a stronger defense. Producing one such adjuvant in yeast promises to make it less expensive and more widely available.
A person wearing a face covering receives a band-aid after a vaccine.

Third COVID-19 Vaccine Booster Improves Antibody Responses for Vulnerable Patients

A major clinical trial has found that an additional COVID-19 vaccine dose led to the majority of clinically extremely vulnerable people mounting defensive antibodies against the virus.
immunofluorescent staining shows a lymph node that has been significantly expanded in mice with the help of the biomaterial MPS-vaccine (on the right), next to a lymph node taken from non-treated control mice (on the left) at the same time post-vaccination.

Biomaterial Vaccine Enhances Lymph Node Expansion and Boosts Anti-Tumor Immunity

A biomaterial vaccine enhances and sustains lymph node expansion following vaccination, boosting anti-tumor immunity in an animal model.
A needle inserted into a vaccine vial.

Experimental mRNA Brain Cancer Vaccine Evaluated in Small Trial

A new mRNA vaccine has shown promise in activating the immune system against a highly lethal type of brain tumor, according to results from a first-in-human clinical trial of four adult patients with glioblastoma.
Epstein-Barr virus (EBV) stained with Hematoxylin and eosin (HE)

Epstein-Barr Virus, Multiple Sclerosis and Cancer: Looking Back at 60 Years of Research

In this interview, Professor Lawrence Young discusses the current interest in Epstein-Barr virus (EBV) vaccines for combatting multiple sclerosis and his thoughts on the future direction of EBV research.
Ribosome translating mRNA into a polypeptide chain.
Industry Insight

Tuning the Therapeutic Properties of tRNAs To Treat Rare Diseases

Michelle C. Werner discusses how tRNAs could transform the drug development paradigm from gene-centric to gene-agnostic and accelerate new therapies for 30 million or more patients whose genetically driven disease can be classified under Stop Codon Disease.